〔Abstract〕 Objective To observe the clinical effect of mifepristone combined with methotrexate in the treatment of patients with tubal pregnancy. Methods A total of 86 patients with tubal pregnancy treated in Zhumadian Traditional Chinese Medicine Hospital from January 2020 to December 2021 were divided into a control group and an observation group by lottery, with 43 cases in each group.The control group was treated with methotrexate, and the observation group was treated with mifepristone combined with methotrexate, and the effects of the two groups were compared. Results The total effective rate of the observation group was 93.02 %, higher than 72.09 % of the control group, the difference was statistically significant (P < 0.001). The time of disappearance of abdominal pain, the time of cessation of vaginal bleeding, the time of disappearance of pregnancy sac and the time of menstruation in the observation group were shorter than those in the control group, the difference were statistically significant (P < 0.001). After treatment, the levels of vascular endothelial growth factor (VEGF) and human chorionic gonadotropin β (β–HCG) in the two groups were decreased to different degrees, the differences were statistically significant (P < 0.001), and the levels of VEGF and β -HCG in the observation group were lower than those in the control group, the differences were statistically significant (P < 0.01). There was no significant difference in adverse reactions between the two groups before treatment (P > 0.05). Conclusion In patients with tubal pregnancy, mifepristone combined with methotrexate can quickly relieve the clinical symptoms of patients, significantly reduce the levels of VEGF, β -HCG, and pelvic mass diameter, without increasing the adverse reactions.